Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Catalyst Pharmaceuticals Ownership Summary


Catalyst Pharmaceuticals is owned by 80.20% institutional investors, 6.28% insiders, and 13.53% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 16.33% of CPRX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.53% of its assets in Catalyst Pharmaceuticals shares.

CPRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCatalyst Pharmaceuticals80.20%6.28%13.53%
SectorHealthcare Stocks 279.46%10.61%-190.07%
IndustryBiotech Stocks 64.06%10.67%25.27%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de19.43M16.33%$405.40M
Blackrock18.69M16.01%$289.58M
Vanguard group8.43M7.09%$175.96M
State street5.80M4.87%$120.97M
Deerfield management company, l.p. (series c)3.13M2.63%$65.39M
Dimensional fund advisors lp3.01M2.53%$62.88M
Pacer advisors2.96M2.49%$61.68M
Goldman sachs group2.80M2.36%$58.49M
Renaissance2.71M2.28%$56.48M
Geode capital management2.67M2.24%$55.64M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tanaka capital management153.29K7.31%$3.20M
Gables capital management417.55K4.20%$8.71M
Jw asset management413.39K4.10%$8.63M
Qsv equity investors84.06K1.69%$1.75M
Knott david m jr210.00K1.58%$4.38M
Resolute capital asset partners137.50K1.54%$2.87M
Deerfield management company, l.p. (series c)3.13M1.24%$65.39M
Mesirow institutional investment management742.29K1.19%$15.49M
Ikarian capital349.65K0.99%$7.30M
Moody aldrich partners215.66K0.83%$4.50M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group2.80M0.01%1.33M
Blackrock18.69M0.01%962.28K
Macquarie group682.65K0.02%682.65K
Ubs group722.86K0.00%510.01K
Abrdn484.67K0.02%484.67K

Top Sellers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)3.13M1.24%-3.10M
Morgan stanley1.01M0.00%-786.18K
Point72 asset management---618.30K
Brandywine global investment management---392.12K
Deutsche bank ag\200.40K0.00%-377.81K

New Positions

HolderShares% AssetsChangeValue
Macquarie group682.65K0.02%682.65K$14.25M
Abrdn484.67K0.02%484.67K$10.11M
Raymond james financial329.98K0.00%329.98K$6.89M
Clark capital management group207.73K0.03%207.73K$4.34M
Renaissance group202.76K0.18%202.76K$4.23M

Sold Out

HolderChange
Coppell advisory solutions-8.00
Mendota financial group-12.00
Richards, merrill & peterson-15.00
Aspire private capital-20.00
Financial gravity asset management-21.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20253616.80%97,419,101-0.16%801.19%193-4.46%11933.71%
Dec 31, 20243294.44%99,023,9753.92%831.30%19521.88%87-17.14%
Sep 30, 202431314.65%95,228,606-1.82%801.16%15925.20%10418.18%
Jun 30, 2024270-96,978,1880.88%831.02%126-20.75%8726.09%
Mar 31, 20242704.25%96,131,18613.87%901.44%15939.47%69-25.81%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF6.75M5.53%-3.60K
Vanguard Total Stock Mkt Idx Inv3.69M3.03%112.01K
Vanguard US Total Market Shares ETF3.55M2.91%3.78K
iShares Russell 2000 ETF2.89M2.37%1.42K
First Trust NYSE Arca Biotech ETF1.89M1.59%-
Vanguard Institutional Extnd Mkt Idx Tr1.73M1.42%15.66K
SPDR® S&P Biotech ETF1.18M0.97%1.53K
Fidelity Small Cap Index1.11M0.91%3.79K
iShares S&P Small-Cap 600 Growth ETF1.00M0.82%-
iShares Russell 2000 Growth ETF986.04K0.81%-

Recent Insider Transactions


DateNameRoleActivityValue
Jun 11, 2025Sundaram Preethi Chief Strategy OfficerSell$42.27K
Jun 10, 2025Sundaram Preethi Chief Strategy OfficerSell$61.38K
Jun 09, 2025MCENANY PATRICK J Chairman of Board of DirectorsSell$4.48M
Jun 06, 2025MCENANY PATRICK J Chairman of Board of DirectorsSell$733.00K
May 30, 2025Daly Richard J President and CEOBuy$1.74M

Insider Transactions Trends


DateBuySell
2025 Q2-7
2025 Q1-5
2024 Q4-14
2024 Q3-7
2024 Q2-5

CPRX Ownership FAQ


Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 80.20%, followed by 6.28% insiders and 13.52% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 64.06%, which Catalyst Pharmaceuticals exceeds.

Who owns the most shares of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (19.43M shares, 16.33%), Blackrock (18.69M shares, 16.01%), and Vanguard group (8.43M shares, 7.09%). Together, they hold 39.43% of Catalyst Pharmaceuticals’s total shares outstanding.

Does Blackrock own Catalyst Pharmaceuticals?

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Who is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tanaka capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.31% of its assets in 153.29K Catalyst Pharmaceuticals shares, valued at 3.2M$.

Who is the top mutual fund holder of Catalyst Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.53% of its total shares outstanding invested in 6.75M Catalyst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools